Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 12:24 PM
Ignite Modification Date:
2025-12-24 @ 12:24 PM
NCT ID:
NCT04655261
Eligibility Criteria:
Inclusion Criteria:
* Confirmed diagnosis of previously untreated Chronic Lymphocytic Leukemia (CLL).
* Participant for whom the physician has decided to initiate CLL treatment with Venetoclax combo therapy with Obinutuzumab, according to approved local label up to 4 weeks (28 days) after Obinutuzumab treatment initiation.
Exclusion Criteria:
* Contraindications to Venclexta (Venetoclax) as listed on the approved local label in Russian Federation.
* Creatinine Clearance \< 30 milliLitres/minute.
* Richter syndrome or Transformation of CLL to aggressive non-Hodgkin lymphoma.
* Participating in a clinical trial with an investigative drug for CLL.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04655261
Study Brief:
Protocol Section:
NCT04655261